Campbell Soup CompanyCPB
NASDAQ • Consumer Defensive
$20.43
P/E
11.12
PEG
0.02
FCF Yield
—
Rev Growth YoY
-81.0% YoY
Gross Margin
2961.0%
Health Score
4/10
D/E Ratio
1.76
Confidence
LOW
Business Snapshot
Campbell Soup Company is a long-established packaged foods manufacturer, producing iconic brands across soups, snacks, and meals sold primarily in North American retail channels. The company operates in the Consumer Defensive sector, meaning demand for its products tends to be relatively resilient across economic cycles. Based on the available price data and valuation ratios, CPB appears to sit in the large-cap tier, though the market capitalisation figure is not confirmed in this payload.
Financial Health
**Score: 4/10** The reported gross margin of 2,961% and net margin of 548% are almost certainly artefacts of an abnormal accounting period or data normalisation issue and should not be treated as reflective of true operational profitability. Debt/equity of 1.76x indicates a moderately leveraged balance sheet, and a current ratio of 0.77x — below the 1.0x threshold — signals that current liabilities exceed current assets, raising near-term liquidity concerns...
Risk Assessment
- **DATA INTEGRITY:** Gross margin of 2,961% and net margin of 548% are statistically implausible for a packaged foods company and suggest underlying data distortion that undermines the entire financial picture. - **REVENUE DECLINE:** Revenue fell -81.0% year-over-year, an extreme contraction that — if reflecting actual business performance — signals a fundamental deterioration in commercial operations. - **LIQUIDITY:** Current ratio of 0.77x means current liabilities exceed current assets, which could constrain operational flexibility or debt servicing in the near term. - **PRICE MOMENTUM:** The stock is trading near its 52-week low of $20.32, having fallen from a 52-week high of $39.04 — a decline of approximately 48% — with a confirmed death cross in moving averages indicating sustained downward technical pressure. - **ANALYST CONSENSUS:** Only 11% of analysts rate the stock a Buy, with 46% on Hold and the overall consensus at Sell, reflecting broad Wall Street scepticism at the current price level. ---...